Cerebrolysin
A mixture of low-molecular-weight neuropeptides and amino acids derived from pig brain tissue, used for cognitive disorders and brain injury recovery.
Common Dosage
5ml - 30ml IV/IM daily for 10-20 days
Category
Nootropic
- Neuroregeneration
- Cognitive enhancement
- Stroke recovery
- Alzheimer's support
Cerebrolysin is a preparation of low-molecular-weight neuropeptides and free amino acids derived from purified pig brain proteins, developed in Austria in the 1940s. It contains biologically active fragments that mimic the effects of endogenous neurotrophic factors including BDNF, NGF, and GDNF. It is approved in over 40 countries for stroke, traumatic brain injury (TBI), and dementia — making it the most clinically validated complex neuropeptide preparation available. The breadth of its regulatory approval is remarkable for a compound not approved by the FDA.
Cerebrolysin's activity is attributed to its mixture of neurotrophic peptide fragments that penetrate the blood-brain barrier and exert BDNF-like, NGF-like, and GDNF-like activity. These factors promote neuronal survival, inhibit apoptosis following ischemia, stimulate synaptogenesis, and support neuroplasticity mechanisms involved in recovery from brain injury. The combination of multiple neurotrophic analogues may provide broader coverage than single-factor approaches.
- Acute ischemic stroke — approved treatment in multiple countries
- Traumatic brain injury recovery
- Vascular dementia
- Alzheimer's disease — significant Cochrane-reviewed clinical trial evidence
- ADHD in children — studied in Eastern European clinical settings
- Cognitive enhancement in healthy individuals
Stroke Recovery Meta-Analysis
Multiple Cochrane systematic reviews of Cerebrolysin in ischemic stroke have shown consistent improvements in neurological outcomes and functional recovery, particularly for moderate-to-severe strokes. The evidence base is stronger than most nootropic compounds but remains somewhat heterogeneous.
Alzheimer's Disease Trials
Clinical trials in Alzheimer's patients have shown improvements in cognitive test scores (ADAS-cog, CGI-C) with Cerebrolysin treatment courses, with effects more pronounced in mild-to-moderate Alzheimer's. Some trials suggest disease-modifying potential through amyloid metabolism effects.
Athletes and Cognitive Optimization
High-achieving individuals using Cerebrolysin for cognitive optimization report substantial improvements in processing speed, working memory, and motivation during treatment courses — consistent with its BDNF and synaptogenic activity.
- Derived from pig brain tissue — religious or ethical concerns for some users; prion disease risk is theoretical but considered negligible with current manufacturing standards
- IV or IM administration required — cannot be taken orally; requires injection technique
- Dizziness, headache, and injection site pain are common
- Fever is a rare but documented side effect
- Requires medical supervision at clinical doses (5–30ml) due to administration demands
- Not FDA-approved — access and quality control outside approved countries is variable
- Dizziness
- Headache
- Injection site pain
- Fever (rare)